Your browser doesn't support javascript.
loading
[Preliminary effects of toripalimab combined with axitinib in the treatment of advanced renal cell carcinoma].
Zhou, L; Xu, H Y; Yan, X Q; Li, S M; Chi, Z H; Si, L; Cui, Z L; Li, J; Wu, X W; Guo, J; Sheng, X N.
Affiliation
  • Zhou L; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Xu HY; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Yan XQ; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Li SM; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Chi ZH; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Si L; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Cui ZL; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Li J; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Wu XW; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Guo J; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
  • Sheng XN; Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China.
Zhonghua Yi Xue Za Zhi ; 102(2): 136-140, 2022 Jan 11.
Article in Zh | MEDLINE | ID: mdl-35012303
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Antibodies, Monoclonal, Humanized / Axitinib / Kidney Neoplasms / Antineoplastic Agents Type of study: Observational_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: Zh Journal: Zhonghua Yi Xue Za Zhi Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Antibodies, Monoclonal, Humanized / Axitinib / Kidney Neoplasms / Antineoplastic Agents Type of study: Observational_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: Zh Journal: Zhonghua Yi Xue Za Zhi Year: 2022 Document type: Article Affiliation country: Country of publication: